The Kerala High Court has allowed a breast cancer patient to be impleaded in a crucial petition challenging the high cost of the drug Ribociclib. The case seeks to ensure affordable access to life-saving medication.

  • Kerala HC permits a new patient to join the litigation regarding expensive cancer drugs.
  • The petition targets the 'exorbitant' pricing of the medication Ribociclib.
  • Medical institutions have been directed to evaluate cheaper alternatives like Palbociclib.

Kochi: In a significant development for patient rights, the Kerala High Court has allowed a breast cancer patient from Malappuram to be impleaded in a petition concerning the 'exorbitant' costs of the life-saving drug Ribociclib. The legal proceedings highlight the intense struggle between pharmaceutical patent protections and the fundamental right to affordable healthcare.

The original petition was filed by a patient diagnosed with HR Positive HER2-Negative Metastatic Breast Cancer. She had sought directives from the Central Government to take over the medication’s patent to make it available at the lowest possible price. Tragically, the petitioner passed away while the case was still pending. Following her demise, another patient suffering from a similar condition sought to be added to the plea to ensure the legal fight continues.

Read Also:Jharkhand High Court Orders RPF Constable to Pay ₹30 Lakh Alimony to First Wife and Son

Judicial Intervention and Suo Motu Action

Justice Harishankar V. Menon observed that since the new petitioner is also undergoing treatment with Ribociclib, she has a direct interest in the outcome of the case. The court has taken up the matter suo motu, recognizing the broader public interest involved in regulating the pricing of essential medicines.

The battle over drug pricing is not just a legal dispute; it is a fight for the survival of patients who are being priced out of life.

The court has issued specific directives to the National Cancer Institute (NCI), Jhajjar, Chittaranjan National Cancer Institute (CNCI), Kolkata, Regional Cancer Centre (RCC), Thiruvananthapuram, and the Drug Controller General of India (DCGI). These bodies must investigate whether Palbociclib, a cheaper alternative, can be safely used in place of Ribociclib.

The Pharmaceutical Conflict

Major pharmaceutical players, including Eli Lilly and Company and Novartis AG, have argued that Palbociclib serves as a viable and cheaper alternative already used across the country. However, the Amicus Curiae appointed by the court has raised critical concerns. She argued that the CDSCO data does not conclusively prove that the two drugs are interchangeable, noting that their clinical and toxicological profiles differ significantly.

Why This Matters

BozokMedia analysis shows that this case could set a massive precedent for pharmaceutical patent laws in India. If the court leans towards government intervention in patents for essential medicines, it could drastically lower the cost of oncology treatments nationwide, but it may also trigger intense legal battles with global pharmaceutical giants regarding intellectual property rights.

Did You Know?: Targeted cancer therapies, while highly effective, are among the most expensive categories of medication in the global pharmaceutical market.

Frequently Asked Questions

1. What is the core issue of this petition?
The petition challenges the extremely high cost of the breast cancer drug Ribociclib and asks the government to intervene via patent acquisition.

2. Are the two drugs, Ribociclib and Palbociclib, identical?
While both are used for cancer, experts argue they have different clinical profiles and should not be swapped without expert oncological guidance.